Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Agios Pharmaceuticals (NASDAQ:AGIO) and raises the price target from $33 to $53.
June 04, 2024 | 3:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Agios Pharmaceuticals but has raised the price target from $33 to $53, indicating a more optimistic outlook on the stock's potential.
The raised price target from $33 to $53 by Goldman Sachs suggests a more optimistic view on Agios Pharmaceuticals' future performance, which could positively impact the stock price in the short term despite the Neutral rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100